The pathogenic role of the adaptive immune response to modified LDL in diabetes

Frontiers in Endocrinology

Volumn 3, Issue JUN, 2012, Pages

  Virella, Gabriel ^a   Lopes Virella, Maria F ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Autoimmune response to modified LDL; Diabetic complications; Immune complexes; LDL modification in diabetes; Nephropathy; Oxidized LDL; Oxidized LDL antibodies

Indexed keywords

EID: 84870352198     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00076     Document Type: Article

References (91)

1. Al Gadban, M. M., Smith, K. J., Soo-davar, F., Piansay, C., Chassereau, C., Twal, W. O., Klein, R. L., Virella, G., Lopes-Virella, M. F., and Ham-mad, S. M. (2010). Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxida-tive stress. PLoS ONE 5, e12534. doi:10.1371/journal.pone.0012534
2. Andersson, J., Libby, P., and Hansson, G. K. (2010). Adaptive immunity and atherosclerosis. Clin. Immunol. 134, 33-46.
3. Arai, K., Kita, T., Yokode, M., Narumiya, S., and Kawai, C. (1989). Multiple receptors for modified LDL in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized LDL. Biochem. Biophys. Res. Commun. 159, 1375-1379.
4. Atchley, D. H., Lopes-Virella, M. F., Zheng, D., and Virella, G. (2002). Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 45, 1562-1571.
5. Berliner, J. A., Territo, M. C., Sevanian, A., Raimin, S., Kim, J. A., Bamshad, B., Ester-son, M., and Fogelman, A. M. (1990). Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85, 1260-1266.
6. Blankenberg, S., Rupprecht, H. J., Poirier, O., Bickel, C., Smieja, M., Hafner, G., Meyer, J., Cambien, F., and Tiret, L. (2003). Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107, 1579-1585.
7. Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L. L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C., Kashyap, Y., Stern, D. M.,and Schmidt, A. M. (2002). RAGE blockade stabilizes established atherosclerosis in diabetic apolipopro-tein E-null mice. Circulation 106, 2827-2835.
8. Chen, J. H., Riazy, M., Wang, S. W., Dai, J. M., Duronio, V., and Stein-brecher, U. P. (2010). Sphingosine kinase regulates oxidized low density lipoprotein-mediated calcium oscillations and macrophage survival. J. Lipid Res. 51, 991-998.
9. Choi, S. H., Harkewicz, R., Lee, J. H., Boullier, A., Almazan, F., Li, A. C., Witztum, J. L., Bae, Y. S., and Miller, Y. I. (2009). Lipopro-tein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ. Res. 104, 1355-1363.
10. Colley, K. J., Wolfert, R. L., and Cobble, M. E. (2011). Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J. 2, 27-38.
11. Crowley, M. T., Costello, P. S., Fitzer-Attas, C. J., Turner, M., Meng, F., Lowell, C., Tybulewicz, V. L., and DeFranco, A. L. (1997). A critical role for Syk in signal trans-duction and phagocytosis mediated by Fcgamma receptors on macrophages. J. Exp. Med. 186, 1027-1039.
12. Datta, S. R., Brunet, A., and Greenberg, M. E. (1999). Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927.
13. de Boer, O. J., van der Wal, A. C., Houtkamp, M. A., Ossewaarde, J. M., Teeling, P., and Becker, A. E. (2000). Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardio-vasc. Res. 48, 402-408.
14. De Boer, O. J., van der Wal, A. C., Verhagen, C. E., and Becker, A. E. (1999). Cytokine secretion profilesof cloned T cells from human aortic atherosclerotic plaques. J. Pathol. 188, 174-179.
15. Endemann, G., Stanton, L. W., Madden, K. S., Bryant, C. M., White, R. T., and Protter, A. A. (1993). CD36 is a receptor for oxidized LDL. J. Biol. Chem. 268, 11811-11818.
16. Fogelman, A. M., Schechter, I., Sea-ger, J., Hokom, M., Child, J. S., and Edwards, P. A. (1980). Malon-dialdehyde alteration of low density lipoproteins leads to cholesterol ester accumulationinhuman mono-cytes/macrophages. Proc. Natl. Acad. Sci. U.S.A. 77, 2214-2218.
17. Galis, Z. S., Sukhova, G. K., Lark, M. W., and Libby, P. (1994). Increased expression of matrix met-alloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503.
18. Giacco, F., and Brownlee, M. (2010). Oxidative stress and diabetic complications. Circ. Res. 107, 1058-1070.
19. Hammad, S. M., Taha, T. A., Nareika, A., Johnson, K. R., Lopes-Virella, M. F., and Obeid, L. M. (2006). Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. Prostaglandins Lipid Mediat. 79, 126-140.
20. Hammad, S. M., Twal, W. O., Barth, J. L., Smith, K. J., Saad, A. F., Virella, G., Argraves, W. S., and Lopes-Virella, M. F. (2009). Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis 202, 394-404.
21. Henriksen, T., Evensen, S. A., and Car-lander, B. (1979). Injury to human endothelial cells in culture induced by LDL. Scand. J. Clin. Lab. Invest. 39, 361-364.
22. Henriksen, T., Mahoney, M. E., and Steinberg, D. (1983). Enhanced macrophage degradation of biologically modified low density lipopro-tein. Arteriosclerosis 3, 149-158.
23. Hessler, J. R., Morel, D. W., Lewis, L. J., andChisolm,G.M. (1983).Lipopro-tein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3, 215-222.
24. Hoff, H. F., O'Neil, J., Chisolm, G. M., Cole, T. B., Quehenberger, O., Ester-bauer, H., and Jurgens, G. (1989). Modificationof low density lipopro-tein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 9, 538-549.
25. Hoff,H.F.,Zyromski,N.,Armstrong,D., and O'Neil, J. (1993). Aggregation as well as chemical modification of LDL during oxidation is responsible for poor processing in macrophages. J. Lipid Res. 34, 1919-1929.
26. Holvoet, P. (1999). Endothelial dysfunction, oxidation of low-density lipoprotein, and cardiovascular disease. Ther. Apher. 3, 287-293.
27. Holvoet, P., Perez, G., Zhao, Z., Brouw-ers, E., Bernar, H., and Collen, D. (1995). Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 95, 2611-2619.
28. Holvoet, P., Vanhaecke, J., Janssens, S., Van de Werf, F., and Collen, D. (1998). Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98, 1487-1494.
29. Hundal, R. S., Gomez-Munoz, A., Kong, J. Y., Salh, B. S., Marotta, A., Duronio, V., and Steinbrecher, U. P. (2003). Oxidized low density lipoprotein inhibits macrophage apoptosis byblocking ceramide generation, thereby maintaining protein kinase B activation and Bcl-XL levels. J. Biol. Chem. 278, 24399-24408.
30. Jarrett, R. J. (1981). Atherosclerosis, diabetes and obesity. Proc. Nutr. Soc. 40, 209-212.
31. Kahn, B. V., Parthasarathy, S. S., Alexander, R. W., and Medford, R. M. (1995). Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J. Clin. Invest. 95, 1262-1270.
32. Koenig, W., and Khuseyinova, N. (2007). Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler. Thromb. Vasc. Biol. 27, 15-26.
33. Kugiyama, K., Sakamoto, T.,Musumi,I., Sugiyama, S., Ohgushi, M., Ogawa, H., Horiguchi, M., and Yasue, H. (1993). Transferrable lipids in oxidized LDL stimulate PAI-1 and inhibit tPA release from endothelial cells. Circ. Res. 73, 335-343.
34. Kume, N., Cybulsky, M. I., and Gimbrone, M. A. J. (1992). Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90, 1138-1144.
35. Langer, T., Strober, W., and Levy, R. I. (1972). The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J. Clin. Invest. 51, 1528-1536.
36. Li, W., Febbraio, M., Reddy, S. P., Yu, D. Y., Yamamoto, M., and Silverstein, R. L. (2010). CD36 participates in a signaling pathway that regulates ROS formationinmurineVSMCs.J. Clin. Invest. 120, 3996-4006.
37. Libby, P., and Theroux,P. (2005). Patho-physiology of coronary artery disease. Circulation 111, 3481-3488.
38. Lim, W. S., Timmins, J. M., Sei-mon, T. A., Sadler, A., Kolodgie, F. D., Virmani, R., and Tabas, I. (2008). Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. Circulation 117, 940-951.
39. Loftus,I.M., Naylor,A. R., Bell,P.R., and Thompson, M. M. (2001). Plasma MMP-9 - amarker of carotid plaque instability. Eur. J. Vasc. Endovasc. Surg. 21, 17-21.
40. Lopes-Virella, M. F., Binzafar, N., Rack-ley, S., Takei, A., La Via, M., and Virella, G. (1997). The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135, 161-170.
41. Lopes-Virella, M. F., Griffith, R. L., Shunk, K. A., and Virella, G. T. (1991). Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscl. Thromb. 11, 1356-1367.
42. Lopes-Virella, M. F., Hunt, K. J., Baker, N. L., Lachin, J., Nathan, D. M., and Virella, G. (2011a). The levels of oxidized ldl and age- ldl in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 60, 582-589.
43. Lopes-Virella, M. F., Baker, N. L., Hunt, K. J., Lachin, J., Nathan, D., and Virella, G. (2011b). Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis 214, 462-467.
44. Lopes-Virella, M. F., Carter, R. E., Baker, N. L., Lachin, J., Virella, G., and Group, D. E. R. (2012a). High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrol. Dial. Transplant. 27, 1416-1423.
45. Lopes-Virella, M. F., Hunt, K. J., and Baker, N. L., Moritz, T., Virella, G. and The VADT Group of Investigators. (2012b). Levels of MDA - LDL in circulating immune complexes predict myocardial infarction in the VADT study in the Veterans Affairs Diabetes Trial (VADT). J. Clin. Lipidol. 6, 256.
46. Lopes-Virella, M. F., Baker, N. L., Hunt, K. J.,Lyons,T. J., Jenkins,A.J.,Virella, G., and The DCCT/EDIC Study Group. (2012c). The concentration of age-modified LDL and oxidized LDL in circulating immune complexes is associated with progression of retinopathy in type 1 diabetes. Diabetes Care 35, 1333-1340.
47. Lopes-Virella, M. F., McHenry, M. B., Lipsitz, S., Yim, E., Wilson, P. F., Lackland, D. T., Lyons, T., Jenkins, A. J., and Virella, G. (2007). Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 190, 359-369.
48. Lopes-Virella, M. F., and Virella, G. (2003). The role of immune and inflammatory processesinthe development of macrovascular disease in diabetes. Front. Biosci. 8, s750-s768.
49. Lopes-Virella, M. F., and Virella, G. (2010). Clinical significance of thehumoral immune responseto modified LDL.Clin. Immunol.134,55-65.
50. Lundberg, A. M., and Hansson, G. K. (2010). Innate immune signals in atherosclerosis. Clin. Immunol. 134, 5-24.
51. Luo, Y., Pollard, J. W., and Casadevall, A. (2010). Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway. J. Biol. Chem. 285, 4232-4242.
52. Miller, Y. I., Choi, S. H., Fang, L., and Tsimikas, S. (2010). Lipopro-tein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell. Biochem. 51, 229-251.
53. Mironova, M., Virella, G., and Lopes-Virella, M. F. (1996). Isolation and characterization of human antiox-idized LDL autoantibodies. Arte-rioscler. Thromb. Vasc. Biol. 16, 222-229.
54. Mironova, M. A., Klein, R. L., Virella, G. T., and Lopes-Virella, M. F. (2000).Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 49, 1033-1041.
55. Moreno, P. R., Murcia, A. M., Pala-cios, I. F., Leon, M. N., Bernardi, V. H., Fuster, V., and Fallon, J. T. (2000). Coronary composition and macrophage infiltration in atherec-tomy specimens from patients with diabetes mellitus. Circulation 102, 2180-2184.
56. Nagarajan, S. (2007). Anti-OxLDL IgG blocks OxLDL interaction with CD36, but promotes Fcgam-maR, CD32A-dependent inflammatory cell adhesion. Immunol. Lett. 108, 52-61.
57. Oksjoki, R., Kovanen, P. T., Lindst-edt, K. A., Jansson, B., and Pen-tikainen, M. O. (2006). OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler. Thromb. Vasc. Biol. 26, 576-583.
58. Orekhov, A. N., Kalenich, O. S., Ter-tov, V. V., and Novikov, I. D. (1991). Lipoprotein immune complexes as markers of atherosclerosis. Int. J. Tissue React. 13, 233-236.
59. Orekhov, A. N., Kalenich, O. S., Tertov, V. V., Perova, N. V., Novikov Iy, D., Lyakishev, A. A., Deev, A. D., and Ruda,M. (1995). Diagnosticvalue of immune cholesterol as a marker for atherosclerosis. J. Cardiovasc. Risk 2, 459-466.
60. Palinski, W., Yla-Herttuala, S., Rosen-feld,M. E., Butler,S.W.,Socher,S. A., Parthasarathy, S., Curtiss, L. K., and Witztum, J. L. (1990). Antisera and monoclonal antibodies specific forepitopes generated during oxidative modification of low density lipopro-tein. Arteriosclerosis 10, 325-335.
61. Pelisek, J., Rudelius, M., Zepper, P., Poppert, H., Reeps, C., Schuster, T., and Eckstein, H. H. (2009). Multiple biological predictors for vulnerable carotid lesions. Cerebrovasc. Dis. 28, 601-610.
62. Penn,M. S., and Chisolm,G. M. (1994). Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 108, S21-S29.
63. Quinn, M. T., Parthasarathy, S., Fong, L. G., and Steinberg, D. (1987). Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of mono-cyte/macrophages during atheroge-nesis. Proc. Natl. Acad. Sci. U.S.A. 84, 2995-2998.
64. Rajavashisth, T. B., Andalibi, A., and Territo, M. C. (1990). Induction of endothelial cell expression of gran-ulocyte and macrophage colony-stimulating factors by modified LDL. Nature 344, 254-257.
65. Saad, A. F., Virella, G., Chassereau, C., Boackle, R. J., and Lopes-Virella, M. F. (2006). OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J. Lipid Res. 47: 1975-1983.
66. Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., Cao, R., Yan, S. D., Brett, J., and Stern, D. (1995). Advanced glyca-tion endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells andinmice. A potential mechanism for theaccel-erated vasculopathy of diabetes. J. Clin. Invest. 96, 1395-1403.
67. Seimon, T., and Tabas, I. (2009). Mechanisms and consequences of macrophage apoptosis inatheroscle-rosis. J. Lipid Res. 50(Suppl.), S382- S387.
68. Shah, P. K. (2002). Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog. Cardiovasc. Dis. 44, 357-368.
69. Shalhoub, J., Falck-Hansen, M. A., Davies, A. H., and Monaco, C. (2011). Innate immunity and monocyte-macrophage activation in atherosclerosis. J. Inflamm. (Lond.) 8, 9.
70. Silverstein, R. L. (2009). Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress. Clin. Lipidol. 4, 767.
71. Silverstein, R. L., Li, W., Park, Y. M., and Rahaman, S. O. (2010).Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans. Am. Clin. Climatol. Assoc. 121, 206-220.
72. Smith, K. J., Twal, W. O., Soodavar, F., Virella, G., Lopes-Virella, M. F., and Hammad, S. M. (2010). Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexesinmacrophages. J. Biol. Chem. 285, 15985-15993.
73. Sparrow, C. P., Parthasarathy, S., and Steinberg, D. (1989). A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J. Biol. Chem. 264, 2599-2604.
74. Steinbrecher, U. P. (1987). Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262, 3603-3608.
75. Steinbrecher, U. P., Fisher, M., Witz-tum, J. L., and Curtiss, L. K. (1984). Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J. Lipid Res. 25, 1109-1116.
76. Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., Lacy-Hulbert, A., El Khoury, J., Golenbock, D. T., and Moore, K. J. (2010). CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161.
77. Takei, A., Huang, Y., and Lopes-Virella, M. F. (2001). Expression of adhesion molecules by human endothe-lial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL. Atherosclerosis 154, 79-86.
78. Tohyama,Y., and Yamamura,H. (2009). Protein tyrosine kinase, syk: a key player in phagocytic cells. J. Biochem. 145, 267-273.
79. Viita, H., Narvanen, O., and Yla-Herttuala, S. (1999). Different apolipoprotein B breakdown patterns in models of oxidized low density lipoprotein. Life Sci. 65, 783-793.
80. Virella,G. (2007)."Biosynthesis, metabolism and biological properties of immunoglobulins," in Medical Immunology, ed. G. Virella (New York: Informa), 65-72.
81. Virella, G., Atchley, D. H., Koski-nen, S., Zheng, D., and Lopes-Virella, M. (2002). Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin. Immunol. 105, 81-92.
82. Virella, G., Carter, R. E., Saad, A., Cross-well, E. G., Game, B. A., and Lopes-Virella, M. F. (2008). Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin. Immunol. 127, 394-400.
83. Virella, G., Derrick, M. B., Pate, V., Chassereau, C., Thorpe, S. R., and Lopes-Virella, M. F. (2005).Development of capture assays for different modifications of human low-density lipoprotein.Clin.Diagn. Lab. Immunol. 12, 68-75.
84. Virella, G., Koskinen, S., Krings, G., Onorato, J. M., Thorpe, S. R., and Lopes-Virella, M. (2000). Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin. Immunol. 95, 135-144.
85. Virella, G., and Lopes-Virella, M. F. (2003). Lipoprotein autoantibod-ies: measurement and significance. Clin. Diagn. Lab. Immunol. 10, 499-505.
86. Virella, G., Thorpe, S., Alderson, N. L., Derrick, M. B., Chassereau, C., Rhett, J. M., and Lopes-Virella, M. F. (2004). Definition of the immuno-genic formsofmodified human LDL recognized by human autoantibod-ies andbyrabbithyperimmune antibodies. J. Lipid Res. 45, 1859-1867.
87. Virella, G., Virella, I., Leman, R. B., Pryor, M. B., and Lopes-Virella, M. F. (1993). Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23, 95-101.
88. Vlassara, H., Bucala, R., and Striker, L. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70, 138-151.
89. Vlassara, H., Cai, W., Crandall, J., Goldberg, T., Oberstein, R., Dard-aine, V., Peppa, M., and Rayfield, E. J. (2002). Inflammatory mediators are induced by dietary glycotox-ins, a major risk factor for diabeticangiopathy. Proc. Natl. Acad. Sci. U.S.A. 99, 15596-15601.
90. Wendt, T., Bucciarelli, L., Qu, W., Lu, Y., Yan, S. F., Stern, D. M., and Schmidt, A. M. (2002). Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Ath-eroscler. Rep. 4, 228-237.
91. Yla-Herttuala, S., Palinski, W., Butler, S., Picard, S., Steinberg, D., and Witz-tum,J. L. (1994). Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14, 32-40.